> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Tremfya Arthritis Benefits Last Through 2 Years: Janssen
- URL: https://www.fdaweb.com/tremfya-arthritis-benefits-last-through-2-years-janssen/
- Published: 2021-03-18T12:00:00.000Z
- Updated: 2026-09-14T16:51:25.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148914

Janssen says long-term data from the Phase 3 DISCOVER-2a study show that the skin clearance, joint symptom relief, and safety of Tremfya (guselkumab), previously seen at 24 and 52 weeks in adults with active psoriatic arthritis, continued through week 112\. “These findings also confirmed that the robust efficacy Tremfya demonstrated in patients at week 24 on physical function, physical aspects of health-related quality of life, and resolution of enthesitisb and dactylitisc was also seen through week 100,” a company [statement](https://www.jnj.com/new-phase-3-data-show-first-in-class-tremfya-guselkumab-achieved-complete-skin-clearance-and-favorable-joint-efficacy-in-adult-patients-with-active-psoriatic-arthritis-psa-through-two-years?ref=fdaweb.com) says.

Tremfya is described as the first and only IL-23 inhibitor therapy approved by FDA to treat both adults with active psoriatic arthritis and adults with moderate to severe plaque psoriasis.